Mcap of nine of top-10 most valued firms surges by Rs 2.34 lakh crore; Reliance biggest gainer
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
39 minutes ago
- Economic Times
Alembic Pharma shares rally 12% on USFDA nod for cancer drug
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Alembic Pharmaceuticals climbed as much as 12% on Monday to Rs 1,089.80 on BSE after the company received final approval from the US Food and Drug Administration (USFDA) for its generic version of Doxorubicin Hydrochloride Liposome Injection , a cancer treatment a press release issued Sunday, the company announced that it had received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose company noted, 'The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation.'The injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. 'Refer to label for detailed indication,' the company IQVIA data, Alembic estimated the market size of Doxorubicin Hydrochloride Liposome Injection in the U.S. to be $29 million for the twelve months ending March cumulative count of USFDA approvals now stands at 224 ANDAs, comprising 201 final approvals and 23 tentative this month, on June 18, the company also received an Establishment Inspection Report (EIR) from the USFDA for its API-III facility in Karakhadi, following an inspection conducted from March 17 to March 21, stock has been on a steady uptrend. It has gained 22.7% in the past year, 2.5% in the past six months, 15.7% over the last three months, and 6.8% in the past a technical standpoint, the stock is currently trading above all its key simple moving averages (5-day to 200-day), signaling bullish momentum across time frames. The Relative Strength Index (RSI) is at 52.4, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at 2.4, staying above its center line though still below its signal stock hit a 52-week high of Rs 1,296.15 on October 9, 2024, and a 52-week low of Rs 725.60 on March 3, 2025.
Mint
40 minutes ago
- Mint
Stock market holidays 2025: NSE, BSE to remain closed on THESE days in July. Check full list here
Stock market holidays 2025: Both stock market exchanges Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) will not witness any holiday in the month of July 2025. However, the market will remain closed for trading for eight days during the month, consisting four Saturdays and Sundays. As per the NSE's trading holiday calendar, the next market holiday in 2025 will be on August 15 in observance of Independence Day, followed by Ganesh Chaturthi on August 27. August 15 - Independence Day August 27 - Ganesh Chaturthi October 2 - Mahatma Gandhi Jayanti/Dussehra October 21 - Diwali Laxmi Pujan October 22 - Balipratipada November 5 - Prakash Gurpurb Sri Guru Nanak Dev Indian benchmark indices, Sensex and Nifty, slipped on Monday, dragged down by losses in financial and auto sectors. This decline came despite a more favourable global risk environment due to easing tensions in the Middle East and a strong revival in foreign capital inflows, which had boosted investor sentiment. The BSE Sensex dropped 321 points, or 0.38%, to 83,737, while the NSE Nifty fell 82 points, or 0.32%, slipping below the 25,600 mark. Last week, both Sensex and Nifty closed with gains, buoyed by improved market sentiment and reduced geopolitical risks. The indices now hover approximately 2.5% below their all-time highs reached in September. 'The Nifty ended 88 points higher, settling at 26738. Technically speaking, and like we have been highlighting, a trending move post the over month-long consolidation is already underway. We are now testing an important upside hurdle between 25640 and 25740 followed by a rising channel peak around 25800, so once we clear this zone, the next logical objective will be the all-time high at 26277. Immediate support lies at 25400 followed by 25250. Global cues are positive this morning, with Japan leading the gains in Asia and US futures in the green," said Akshay Chinchalkar, Head of Research, Axis Securities. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
43 minutes ago
- Time of India
Zen Technologies shares gain over 3% after securing Indian patent in defence tech
Technical Overview & Valuation Check: Zen Technologies Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Zen Technologies gained 3.5% on Monday to the day's high of Rs 1,992 after the company announced the grant of its 54th Indian patent The newly awarded patent, titled 'Single ILU Long Pass Filter,' represents a notable advancement in laser-based military training systems and reinforces Zen's growing footprint in defence technology . With this addition, the company's total global patent count has reached 82, highlighting its strong focus on indigenous R&D and innovation in defence simulation The patented technology enables the integration of visible and infrared laser beams into a single, stable output, enhancing the accuracy and realism of combat training simulators . Compared to traditional systems that rely on separate beams and are often prone to alignment issues and high maintenance, Zen's compact design promises greater durability and reduced recalibration needs, especially in rugged field breakthrough strengthens Zen's portfolio of advanced training solutions, supporting the Indian armed forces and global defence clients with state-of-the-art simulation capabilities. The market responded positively to the development, with investors viewing the patent as a value-add in Zen's long-term growth a valuation standpoint, the stock is currently trading at a Price-to-Earnings (PE) ratio of 61.99 and a Price-to-Book (PB) ratio of 10.01, indicating a premium valuation likely driven by its strong growth potential and innovation the technical front, Zen is exhibiting a bullish trend based on moving averages. The stock is trading above 6 out of 8 key Simple Moving Averages (SMAs), including longer-term indicators, reflecting underlying strength. It is marginally below the 20-day and 30-day SMAs, which may be watched for short-term trend confirmation.
